CTLA-4 inhibitors (ipilimumab, tremelimumab) were characterized by a high frequency of hypophysitis, reported in 25–38% of cases, often appearing later (15–20 weeks after treatment initiation). The gene discussed is CTLA4; the disease is hypophysitis.